Eckert & Ziegler BEBIG: Catch prostate cancer in time and treat it gently. The new patient brochure is available now.
(Thomson Reuters ONE) -
Berlin, 24 August 2011; Prostate cancer is the second most frequent type of
cancer in men and is affecting younger and younger patients. If prostate cancer
is detected in good time, it can often be treated effectively and gently,
without impairing the patient's quality of life. This is why it is important
that patients should be informed about the early symptoms and how this carcinoma
can be detected at an early stage, together with adequate details of treatment
options.
Eckert & Ziegler BEBIG have issued a new information brochure about prostate
cancer.The brochure is available in German and English and provides detailed
information about prostate cancer, with clear information about the various
methods of early detection and treatment.
The brochure can be ordered free of charge from:
Eckert & Ziegler BEBIG GmbH
Reference: "Patient Brochure"
Robert-Rössle-Str. 10
13125 Berlin
Tel.: 030941084272
Fax: 030941084410
Mail:dorota.tkaczyk(at)bebig.eu
Download:
http://www.bebig.eu/fileadmin/ibt-
bebig.eu/fileadmin/pdf/PatientBrochure_English.pdf
The brochure tells patients how prostate cancer can be detected at an early
stage and which therapies can then be used. Locally restricted prostate cancer
can be treated in several different ways, which have similar efficacy. One
particularly effective way is to use so-called LDR brachytherapy with extremely
small weakly radioactive implants. Tiny iodine-125 capsules (known as "seeds")
are placed in specific positions in the prostate, ensuring that the dose is
optimally distributed within the target tissue, without exposing the surrounding
organs. Moreover, LDR brachytherapy is highly effective and well tolerated. The
treatment period is short and the patient recovers relatively quickly.
LDR brachytherapy may be performed with products from Eckert & Ziegler BEBIG,
including IsoSeed® (individual seeds) or IsoCord® (seed chains). These have been
successfully used for more than ten years in clinical practice.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB).
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email:ir(at)bebig.eu
Website:www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1540772]
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2011 - 16:32 Uhr
Sprache: Deutsch
News-ID 58949
Anzahl Zeichen: 4046
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: Catch prostate cancer in time and treat it gently. The new patient brochure is available now."
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
